OBJECTIVE: To investigate and compare the molecular mechanisms by which 2 glucocorticoid receptor (GR)-activating compounds, dexamethasone (DEX) and Compound A (CpdA), interfere with the NF-kappaB activation pathway in rheumatoid arthritis (RA) synovial cells. METHODS: Quantitative polymerase chain reaction was performed to detect the tumor necrosis factor alpha (TNFalpha)-induced cytokine gene expression of interleukin-1beta (IL-1beta) and to investigate the effects of DEX and CpdA in RA fibroblast-like synoviocytes (FLS) transfected with small interfering RNA (siRNA) against GR (siGR) compared with nontransfected cells. Immunofluorescence analysis was used to detect the subcellular distribution of NF-kappaB (p65) under the various treatment conditions, and active DNA-bound p65 was measured using a TransAM assay and by chromatin immunoprecipitation analysis of IL-1beta. Signaling pathways were studied via Western blotting of siGR-transfected cells, compared with nontransfected and nontargeting siRNA-transfected control cells, to detect the regulation of phospho-IKK, IkappaBalpha, phospho-p38, phospho-ERK, and phospho-JNK. RESULTS: Both DEX and CpdA efficiently inhibited IL-1beta gene expression in a GR-dependent manner. In addition, CpdA attenuated the TNFalpha-induced nuclear translocation and DNA binding of p65 in RA FLS, via the attenuation of IKK phosphorylation and subsequent IkappaBalpha degradation. CpdA also displayed profound effects on TNFalpha-induced MAPK activation. The effects of CpdA on TNFalpha-induced kinase activities occurred independently of the presence of GR. In sharp contrast, DEX did not affect TNFalpha-induced IKK phosphorylation, IkappaBalpha degradation, p65 nuclear translocation, or MAPK activation in RA FLS. CONCLUSION: DEX and CpdA display a dissimilar molecular mechanism of interaction with the NF-kappaB activation pathway ex vivo. A dual pathway, partially dependent and partially independent of GR (nongenomic), may explain the gene-inhibitory effects of CpdA in RA FLS.
OBJECTIVE: To investigate and compare the molecular mechanisms by which 2 glucocorticoid receptor (GR)-activating compounds, dexamethasone (DEX) and Compound A (CpdA), interfere with the NF-kappaB activation pathway in rheumatoid arthritis (RA) synovial cells. METHODS: Quantitative polymerase chain reaction was performed to detect the tumor necrosis factor alpha (TNFalpha)-induced cytokine gene expression of interleukin-1beta (IL-1beta) and to investigate the effects of DEX and CpdA in RA fibroblast-like synoviocytes (FLS) transfected with small interfering RNA (siRNA) against GR (siGR) compared with nontransfected cells. Immunofluorescence analysis was used to detect the subcellular distribution of NF-kappaB (p65) under the various treatment conditions, and active DNA-bound p65 was measured using a TransAM assay and by chromatin immunoprecipitation analysis of IL-1beta. Signaling pathways were studied via Western blotting of siGR-transfected cells, compared with nontransfected and nontargeting siRNA-transfected control cells, to detect the regulation of phospho-IKK, IkappaBalpha, phospho-p38, phospho-ERK, and phospho-JNK. RESULTS: Both DEX and CpdA efficiently inhibited IL-1beta gene expression in a GR-dependent manner. In addition, CpdA attenuated the TNFalpha-induced nuclear translocation and DNA binding of p65 in RA FLS, via the attenuation of IKK phosphorylation and subsequent IkappaBalpha degradation. CpdA also displayed profound effects on TNFalpha-induced MAPK activation. The effects of CpdA on TNFalpha-induced kinase activities occurred independently of the presence of GR. In sharp contrast, DEX did not affect TNFalpha-induced IKK phosphorylation, IkappaBalpha degradation, p65 nuclear translocation, or MAPK activation in RA FLS. CONCLUSION:DEX and CpdA display a dissimilar molecular mechanism of interaction with the NF-kappaB activation pathway ex vivo. A dual pathway, partially dependent and partially independent of GR (nongenomic), may explain the gene-inhibitory effects of CpdA in RA FLS.
Authors: Tony Huynh; Kitipong Uaesoontrachoon; James L Quinn; Kathleen S Tatem; Christopher R Heier; Jack H Van Der Meulen; Qing Yu; Mark Harris; Christopher J Nolan; Guy Haegeman; Miranda D Grounds; Kanneboyina Nagaraju Journal: J Pathol Date: 2013-10 Impact factor: 7.996
Authors: Ulrike Baschant; Lucien Frappart; Una Rauchhaus; Lisa Bruns; Holger M Reichardt; Thomas Kamradt; Rolf Bräuer; Jan P Tuckermann Journal: Proc Natl Acad Sci U S A Date: 2011-11-14 Impact factor: 11.205
Authors: Ekaterina Lesovaya; Alexander Yemelyanov; Kirill Kirsanov; Alexander Popa; Gennady Belitsky; Marianna Yakubovskaya; Leo I Gordon; Steven T Rosen; Irina Budunova Journal: Cell Cycle Date: 2012-12-19 Impact factor: 4.534
Authors: Mohammad M Ahasan; Rowan Hardy; Christopher Jones; Kirren Kaur; Dominika Nanus; Maria Juarez; Stuart A Morgan; Zaki Hassan-Smith; Cécile Bénézech; Jorge H Caamaño; Martin Hewison; Gareth Lavery; Elizabeth H Rabbitt; Andrew R Clark; Andrew Filer; Christopher D Buckley; Karim Raza; Paul M Stewart; Mark S Cooper Journal: Arthritis Rheum Date: 2012-07
Authors: Karolien De Bosscher; Ilse M Beck; Lien Dejager; Nadia Bougarne; Anthoula Gaigneaux; Sébastien Chateauvieux; Dariusz Ratman; Marc Bracke; Jan Tavernier; Wim Vanden Berghe; Claude Libert; Marc Diederich; Guy Haegeman Journal: Cell Mol Life Sci Date: 2013-06-20 Impact factor: 9.261